CRISM Therapeutics : Admission Document

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document, you should consult your stockbroker, bank manager, solicitor, accountant or other independent professional adviser who specialises in advising on the acquisition of shares and other securities and is duly authorised under the Financial Services and Markets Act 2000 (as amended) ("FSMA"), if you are resident in the UK, or if you are not resident in the UK, from another appropriately authorised independent adviser.

If you have sold or otherwise transferred all of your Existing Ordinary Shares, please send this document together with the accompanying Form of Proxy or Form of Direction, to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or otherwise transferred some of your Existing Ordinary Shares, you should consult with the stockbroker, bank or other agent through whom the sale or transfer was effected.

This document, which comprises an AIM admission document drawn up in accordance with the AIM Rules, has been issued in connection with the application for admission to trading on AIM all of the issued and to be issued Ordinary Shares. This document does not constitute an offer to the public requiring an approved prospectus under section 85 of FSMA and, accordingly, this document does not constitute a prospectus for the purposes of FSMA and the Prospectus Regulation Rules and a copy has not, and will not be, pre-approved or filed with the FCA.

Application will be made for all of the issued and to be issued Ordinary Shares to be admitted to trading on AIM, a market operated by the London Stock Exchange. It is expected that Admission will become effective, and that dealings in the New Ordinary Shares will commence on 31 May 2024. The Existing Ordinary Shares are not dealt on any other recognised investment exchange and no application has been or is being made for the New Ordinary Shares to be admitted to any such exchange.

AIM is a market designed primarily for emerging or smaller companies to which a higher investment risk tends to be attached than to larger or more established companies. AIM securities are not admitted to the Official List of the United Kingdom's Financial Conduct Authority. A prospective investor should be aware of the risks of investing in such companies and should make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Each AIM company is required, pursuant to the AIM Rules for Companies to have a nominated adviser. The nominated adviser is required to make a declaration to the London Stock Exchange on Admission in the form set out in Schedule Two to the AIM Rules for Nominated Advisers. The London Stock Exchange has not itself examined or approved the contents of this document.

Prospective investors should read the whole text of this document and should be aware that an investment in the Company is speculative and involves a high degree of risk and prospective investors should carefully consider the section entitled "Risk Factors" set out in Part II of this document. All statements regarding the Company's current and the Enlarged Group's proposed business, financial position and prospects should be viewed in light of these risk factors.

AMUR MINERALS CORPORATION

(a company incorporated and registered in British Virgin Islands with registered number 1010359)

Conditional Acquisition of Extruded Pharmaceuticals Limited

Share Consolidation

Change of name to CRISM Therapeutics Corporation

Amendment to Memorandum and Articles of Association

Admission of the Enlarged Share Capital to trading on AIM and Notice of General Meeting

SP Angel Corporate Finance LLP

Nominated Adviser and Broker

The Directors and Proposed Directors, whose names appear on page 6 of this document, and the Company accept responsibility, both individually and collectively, for the information contained in this document. To the best of the knowledge and belief of the Company, the Directors and the Proposed Directors (having taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

The Consideration Shares will, upon Admission, rank pari passu in all respects and will rank in full for all dividends and other distributions declared paid or made in respect of the New Ordinary Shares after Admission. It is emphasised that no application is being made for the Enlarged Share Capital to be admitted to the Official List or to any other recognised investment exchange.

SP Angel, which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for the Company as nominated adviser and broker to the Company in connection with the Admission and will not be responsible to any other person for providing the protections afforded to customers of SP Angel or advising any other person in connection with Admission. Its responsibilities as the Company's nominated adviser under the AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange and are not owed to the Company, any Director, Proposed Director or to any other person in respect of his decision to acquire shares in the Company in reliance on any part of this document. SP Angel will not be offering advice and will not otherwise be responsible to anyone other than the Company for providing the protections afforded to clients of SP Angel or for providing advice in relation to the contents of this document or any other matter.

Prospective investors should only rely on the information in this Admission Document. No person has been authorised to give any information or to make any representations other than those contained in this Admission Document in connection with Admission and, if given or made, such information or representations must not be relied upon as having been authorised by or on behalf of the Company, the Directors or SP Angel. No representation or warranty, express or implied, is made by SP Angel as to the accuracy or completeness of such information and nothing contained in this Admission Document is, or shall be relied upon as, a promise or representation by SP Angel as to the past, present or future. Apart from the responsibilities and liabilities, if any, which may be imposed on SP Angel by FSMA or the regulatory regime established under it, SP Angel does not accept any responsibility whatsoever for the contents of this document, and no representation or warranty, express or implied, is made by SP Angel with respect to the accuracy or completeness of this document or any part of it.

Notice convening a General Meeting of Shareholders to be held at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London EC4R 3TT, UK on 29 May 2024 at 10.30 a.m. (or as soon thereafter as the Company's annual general meeting concludes) is set out at the end of this document. A Form of Proxy for holders of Ordinary Shares for use at the General Meeting accompanies this document and, to be valid, must be completed and returned to Link Group at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL.

As an alternative to completing the hard copy Form of Proxy, you can appoint a proxy electronically online at www.signalshares.com and by completing the authentication requirements as set out on the Form of Proxy. Alternatively, you can vote via the LinkVote+ app (refer to the notes to the Notice of Meeting). For an electronic proxy appointment to be valid, your appointment must be received by the Company's registrars, Link Group, PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible but in any event no later than 10.30 a.m. on 24 May 2024.

A Form of Direction for holders of Depositary Interests for use at the General Meeting of Shareholders accompanies this document and, to be valid, must be completed and returned to Link Group at PXS 1, Central Square, 29 Wellington Street, Leeds, LS1 4DL as soon as possible but in any event to be received not later than 10.30 a.m. on 23 May 2024. The return of one or more completed Forms of Proxy or Forms of Direction will not prevent you from attending the General Meeting and voting in person if you wish to do so (and are so entitled).

Depositary Interest holders who are also CREST members may transmit voting instructions by utilising the CREST voting service in accordance with the procedures described in the CREST Manual (refer to the notes to the Notice of Meeting).

If you are an institutional investor you may also be able to submit your instruction electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io and refer to the notes to the Notice of Meeting.

The contents of this Admission Document are not to be construed as legal, business or tax advice. Each prospective investor should consult its, his or her own lawyer, financial adviser or tax adviser for legal, financial or tax advice in relation to any subscription or purchase, or proposed subscription or purchase, of New Ordinary Shares. In making an investment decision, each prospective investor must rely on its, his or her own examination, analysis and enquiry of the Enlarged Group and the terms of the Acquisition, including the merits and risks involved.

Copies of this document will be available free of charge to the public during normal business hours on any day (Saturdays, Sundays and public holidays excepted) at the offices of SP Angel at Prince Frederick House, 35 - 39 Maddox Street, London, W1S 2PP and the registered office of the Company, from the date of this document until one month from the date of Admission in accordance with the AIM Rules. A copy of this document will also be available from the Company's website at www.amurminerals.com before Admission and www.crismtherapeutics.com after Admission.

Without limiting the statutory rights of any person to whom this document is issued, no representation or warranty, express or implied, is made by SP Angel as to the contents of this document. Apart from the responsibilities and liabilities, if any, which may be imposed on SP Angel by FSMA or the regulatory regime established thereunder, no liability whatsoever is accepted by SP Angel for the accuracy of any information or opinions contained in this document, for which the Directors and Proposed Directors are solely responsible, or for the omission of any information from this document for which it is not responsible.

This document does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, securities in any jurisdiction in which such offer or solicitation is unlawful and, in particular, is not for publication or distribution in or into the United States, Canada, Australia, New Zealand, South Africa or Japan, nor in any country or territory where to do so may contravene local securities laws or regulations. The distribution of this document in other jurisdictions may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities law of any such jurisdictions. The New Ordinary Shares have not been, and will not be, registered under the United States Securities Act of 1933 (as amended) or under the securities legislation of any state or other jurisdiction of the United States, any province or territory of Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa and may not be offered or sold, directly or indirectly, within the United States, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa or to or for the account or benefit of any national, citizen or resident of the United States of America, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa or to any US person (within the definition of Regulation S made under the United States Securities Act 1933 (as amended)).

The distribution of this document outside the UK may be restricted by law. No action has been taken by the Company or SP Angel that would permit a public offer of shares in any jurisdiction outside the UK where action for that purpose is required. Persons outside the UK who come into possession of this document should inform themselves about the distribution of this document in their particular jurisdiction. Failure to comply with those restrictions may constitute a violation of the securities laws of such jurisdiction.

Forward looking statements

Certain statements contained in this document are forward looking statements and are based on current expectations, estimates and projections about the potential returns of the Company and industry and markets in which the Company will operate, the Directors' beliefs and assumptions made by the Directors and Proposed Directors. Words such as "expects", "anticipates", "may", "should", "would", "could", "will", "intends", "plans", "believes", "targets", "seeks", "estimates", "aims", "projects", "pipeline" and variations of

2

such words and similar expressions are intended to identify such forward looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate investments and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence, the availability of financing on acceptable terms and changes in the legal or regulatory environment.

Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward looking statements speak only as of the date of this document. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements contained herein to reflect any change in the Company's expectations with regard thereto, any new information or any change in events, conditions or circumstances on which any such statements are based, unless required to do so by law or any appropriate regulatory authority.

Market, economic and industry data

This document contains information regarding the Company's business and the industry in which it operates and competes, which the Company has obtained from various third party sources. Where information contained in this document originates from a third party source, it is identified where it appears in this document together with the name of its source, the Company confirms that such third party information has been accurately reproduced and, so far as the Company is aware and is able to ascertain from information published by the relevant third party, no facts have been omitted which would render the reproduced information inaccurate or misleading.

3

TABLE OF CONTENTS

KEY STATISTICS	5
EXPECTED TIMETABLE OF PRINCIPAL EVENTS	5
DIRECTORS, SECRETARY AND ADVISERS	6
DEFINITIONS	8
GLOSSARY OF TECHNICAL TERMS	13
PART I - LETTER FROM THE CHAIRMAN	16
PART II - RISK FACTORS	39
PART III - TECHNICAL EXPERT'S REPORT	46
PART IV - HISTORICAL FINANCIAL INFORMATION ON THE COMPANY	79
PART V - HISTORICAL FINANCIAL INFORMATION ON EPL	80
PART VI - TAXATION	117
PART VII - ADDITIONAL INFORMATION	120
NOTICE OF GENERAL MEETING	136

4

KEY STATISTICS

Number of Existing Ordinary Shares	1,392,872,315
Number of New Ordinary Shares in issue immediately	8,705,289*
following the Share Consolidation
Number of New Ordinary Shares to be issued pursuant to the Acquisition	23,939,986*
Number of New Ordinary Shares to be issued pursuant to the Bonus Issue	32,875*
Number of New Ordinary Shares in issue upon Admission, following the	32,678,150*
Share Consolidation and Bonus Share Issue and Consideration Share issue
Consideration Shares as a percentage of the Enlarged Share Capital	73.26 per cent.
Estimated Market capitalisation of the Company on Admission	£7.5 million
Estimated value of each New Ordinary Share at Admission	23.0 pence
TIDM with effect from Admission	CRTX
New Ordinary Share ISIN	VGG042401262
New SEDOL	BS60QF6
LEI	213800XFW6MKVCHHPW88
*Assumes that the Share Consolidation Resolution is passed

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Publication of this Admission Document	13	May 2024
Latest time and date for receipt of Forms of Direction	10.30 a.m. on 23 May 2024
Latest time and date for receipt of Forms of Proxy	10.30 a.m. on 24 May 2024
Time and date of the General Meeting	10.30 a.m. on 29 May 2024
Record Date of the Share Consolidation	6.00 p.m. on 30	May 2024
Completion of the Acquisition, Admission of the New Ordinary Shares,	8.00 a.m. on 31 2024
and commencement of dealings on AIM
Expected date for New Ordinary Shares to be credited to CREST accounts	31	May 2024
Despatch of definitive certificate for New Ordinary Shares	by 14 June 2024

All of the above timings refer to London time unless otherwise states. All future times and / or dates referred to in this Document are subject to change at the discretion of the Company and its advisers.

5

DIRECTORS, SECRETARY AND ADVISERS
Existing Directors	Robert William Schafer (Non-ExecutiveChairman)
	Robin Jay Young (Chief Executive Officer)
	Thomas Edward Bowens (Non-ExecutiveDirector)
	Paul Terence Gazzard (Non-ExecutiveDirector)
Proposed Directors	Nermeen Yunus Varawalla (Non-ExecutiveChair)
	Andrew James Webb (Chief Executive Officer)
	Christopher McConville (Chief Scientific Officer)
	Gerald Douglas Beaney (Non-Executive Director)
Registered Office	Kingston Chambers
	PO Box 173
	Road Town
	Tortola
	British Virgin Islands
Company Secretary	Westend Corporate LLP
Website	www.amurminerals.com
Website from Admission	www.crismtherapeutics.com
Nominated Adviser and Broker	SP Angel Corporate Finance LLP
	Prince Fredrick House
	35 - 39 Maddox Street
	London
	W1S 2PP
Solicitors to the Company	Fieldfisher LLP
(UK law)	Riverbank House
	2 Swan Lane
	London
	EC4R 3TT
Solicitors to the Company	Maples and Calder
(BVI law)	Ritter House, PO Box 173
	Road Town
	Tortola VG1110
	British Virgin Islands
Solicitors to EPL	Weightmans LLP
	No 1 Spinningfields
	Hardman Square
	Manchester
	M3 3EB
Solicitors to the Nomad	Hill Dickinson LLP
and Broker	11 Wellington Place
	Leeds
	LS1 4AP
Reporting Accountant	Haysmacintyre LLP
	10 Queen Street Place
	London
	EC4R 1AG

6

Accountants to EPL	Fairhurst Accountants
	Douglas Bank House
	Wigan Lane
	Wigan
	WN1 2TB
Independent Technical Expert	Cambridge Drug Discovery
	35 Tunwells Lane
	Great Shelford
	Cambridge
	CB22 5LJ
Registrars	Link Market Services (Jersey) Limited
	12 Castle Street
	St Helier
	Jersey
	JE2 3RT
Depositary	Link Market Services Trustees Limited
	Central Square
	29 Wellington Street
	Leeds
	LS1 4DL
Public Relations	Buchanan PR
	107 Cheapside
	EC2V 6DN

7

DEFINITIONS

The following definitions apply throughout this document, unless the context requires otherwise or unless otherwise defined:

"£" or "Sterling"	British pounds sterling
"$" or "dollar"	US dollar
"Acquisition"	the proposed acquisition of EPL by the Company, which constitutes
	a reverse takeover pursuant to Rule 14 of the AIM Rules
"Acquisition Agreement" or "SPA"	means the share purchase agreement in respect of the Acquisition
	entered into between the Company and the Sellers and dated
	10 May 2024, further details of which are set out in paragraph 11.3
	of Part VII of this document
"Acquisition Resolution"	the resolution numbered 1 in the Notice to be proposed at the
	General Meeting to approve the Acquisition
"Admission"	the admission of the Enlarged Share Capital to trading on AIM
	becoming effective in accordance with Rule 6 of the AIM Rules
"Admission Document" or	this document dated 13 May 2024
"Document"
"AGM"	the annual general meeting of the Company, convened for
	10.00 a.m. on 29 May 2024
"AIM"	the market of that name operated by the London Stock Exchange
"AIM Rules"	the AIM Rules for Companies published by the London Stock
	Exchange from time to time (including, without limitation, any
	guidance notes or statements of practice) which govern the rules
	and responsibilities of companies whose shares are admitted to
	trading on AIM
"AIM Rules for Nominated	the rules setting out the eligibility, ongoing obligations and certain
Advisers"	disciplinary matters in relation to nominated advisers, as published
	by the London Stock Exchange from time to time
"Amur" or the "Company"	Amur Minerals Corporation, a company incorporated and registered
	in the British Virgin Islands with registered number 1010359
"Articles"	the memorandum and articles of association of the Company as the
	same are in force at any applicable time
"Audit Committee"	the audit committee of the Board, as constituted from time to time
"Authority Resolutions"	the resolutions numbered 3 and 4 in the Notice to be proposed at
	the General Meeting to authorise the Directors to issue Ordinary
	Shares and dis-applypre-emption rights
"Board"	the board of Directors of the Company from time to time, or a duly
	constituted committee thereof including, where the context requires,
	the Directors of the Company on or after Admission
"Bonus Issue"	the issue of the Bonus Issue Shares to the Existing Directors of the
	Company
	8

"Bonus Issue Shares"	the 32,875 New Ordinary Shares issued to Existing Directors of the
	Company pursuant to the Bonus Issue
"BVI"	the British Virgin Islands
"BVI Act"	the BVI Business Companies Act (As Revised) of the BVI
"BVI Register"	the Register of Corporate Affairs in the BVI
"Certificated" or	recorded on the relevant register of the share or security concerned
"in certificated form"	as being held in certificated form in physical paper (that is not in
	CREST)
"ChemoSeed"	an implantable, bioresorbable drug delivery platform developed by
	EPL
"Consideration Shares"	the 23,939,986 New Ordinary Shares to be issued to the Sellers in
	consideration for the transfer of their respective shareholdings in EPL
	to the Company
"CREST"	the computer based system and procedures which enable title to
	securities to be evidenced and transferred without a written
	instrument, administered by Euroclear UK & International in
	accordance with the CREST Regulations
"CREST Regulations"	the Uncertificated Securities Regulations 2001 (SI 2001/3755),
	including: (i) any enactment or subordinate legislation which amends
	those regulations; and (ii) any applicable rules made under those
	regulations or such enactment or subordinate legislation for the time
	being in force
"Depositary"	Link Market Services Trustees Limited acting in its capacity as
	depositary pursuant to the terms of the agreement for the provision
	of depositary services entered into between the Company and Link
	Market Services Trustees Limited
''Depositary Interest''	a depositary interest issued by the Depositary in the ratio of one for
	one in respect of each Ordinary Share deposited with the Depositary
	for conversion to a depositary interest
"Directors"	the Directors of the Company as at Admission, which, where the
	context requires, shall include the Proposed Directors, whose names
	are set out on page 6 of this Document
"Enlarged Group"	the Group and EPL
"Enlarged Share Capital"	the New Ordinary Shares in issue immediately following
	implementation of the Proposals
"Extruded Pharmaceuticals" or	Extruded Pharmaceuticals Limited, a company incorporated in
"EPL"	England & Wales with company number 10048348, and having its
	registered office at Douglas Bank House, Wigan Lane, Wigan,
	Lancashire, United Kingdom, WN1 2TB
"EPL Directors"	the directors of EPL as at the date of this Document, being Andrew
	Webb, Christopher McConville, David Lawton and Brian Murray
"Euroclear UK & International"	Euroclear UK & International Limited, a company incorporated under
or "Euroclear"	the laws of England and Wales with registered number 2878738 and
	the operator of CREST
	9

"Existing Articles"	the existing memorandum and articles of association of the
	Company as at the date of this Document
"Existing Directors"	the directors of the Company on the date of this Document
"Existing Ordinary Shares"	the 1,392,872,315 Ordinary Shares where the Share Consolidation
	has not occurred and which are in issue as at the date of this
	Document
"FCA"	the Financial Conduct Authority of the United Kingdom
"Form of Direction"	The form of direction accompanying this Document for use by the
	holders of Depositary Interests in connection with the General
	Meeting
"Form of Proxy"	the form of proxy accompanying this Document for use by
	Shareholders in connection with the General Meeting
"Founder Shareholders"	Andrew Webb, Christopher McConville, David Lawton and Brian
	Murray
"FSMA"	the Financial Services and Markets Act 2000 (as amended)
"GM" or "General Meeting"	the general meeting of the Company, convened for 10.30 a.m. (or
	as soon thereafter as the Company's AGM concludes) on 29 May
	2024, and any adjournment thereof, notice of which is set out at the
	end of this Document
"Group"	the Company and its subsidiary undertakings
"HMRC"	HM Revenue and Customs
"Independent Director"	a director who is at the relevant time considered by the Board to be
	independent, as determined by reference to the QCA Code
"Irosta"	Irosta Trading Limited, a company incorporated in Cyprus on 9
	October 2003 with registered number 141841
"Kun-Manie"	the Kun-Manie Nickel Copper Sulphate Project located in Amur
	Oblast, Russia
"IFRS"	International Financial Reporting Standards as adopted by the
	European Union
"Lock-in Agreement	the lock-in agreements with each of the Sellers who have agreed
	with the Enlarged Group and SP Angel to restrictions on their ability
	to dispose of New Ordinary Shares held by them
"Locked-in Persons"	the Sellers
"London Stock Exchange"	London Stock Exchange plc
"Name & Articles Resolution"	the resolution numbered 2 in the Notice to be proposed at the
	General Meeting to change the name of the Company, amend and
	restate the Existing Articles and thereby adopt the New Articles
"New Articles"	the proposed amended and restated memorandum and articles of
	association of the Company to be approved at the General Meeting
	pursuant to the Name & Articles Resolution and to be effective from
	when registered by the BVI Registrar
	10